← Leaderboards
Jennifer E. Amengual
Columbia University Health Sciences
$3,970,982
Attributed
$5,984,088
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,984,088 · 2
By mechanism
UG1$4,026,213 · 1
R01$1,957,875 · 1
Top collaborators
- Lisa A. Kachnic4 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Alfred I Neugut$17,537,198
- Anil K Rustgi$51,275,906
- Andrew B Lassman$5,644,772
- Mary Beth Terry$27,685,500
- Katherine D Crew$8,241,673
Others in their field
Other Emerging Leaders on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Research focus
LeadClinical TrialsChemical GroupCell LineAffectCellsAntibody RepertoireB-Cell DevelopmentAcetylationCell DeathAllelesAutomobile DrivingAnalogBiophysicsAntibody AffinityAffinityB-Cell LymphomasBcl6 GeneAggressive CourseBindingApoptosisCell CycleBiological MarkersBiophysical Properties
Grant awards (11)
Columbia University NCI Community Oncology Research Program$1,008,906
UG1 · FY2025 · CA
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$980,169
UG1 · FY2024 · CA
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$1,021,012
UG1 · FY2023 · CA
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$1,016,126
UG1 · FY2022 · CA
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$370,575
R01 · FY2022 · CA · contact PI
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$370,575
R01 · FY2021 · CA · contact PI
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$370,575
R01 · FY2020 · CA · contact PI
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$359,457
R01 · FY2019 · CA · contact PI
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$91,551
R01 · FY2019 · CA · contact PI
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$24,567
R01 · FY2019 · CA · contact PI
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma$370,575
R01 · FY2018 · CA · contact PI